The drug Ticagrelor helps prevent platelets from sticking together, which reduces the likelihood of a blood clot forming, which can close the lumen of a blood vessel. This means that Ticagrelor reduces your chances of having a second heart attack (myocardial infarction) or stroke, or death from a disease related to the heart or blood vessels.

The drug Ticagrelor is taken simultaneously with acetylsalicylic acid in adult patients over the age of 18 with related diseases:

• for the prevention of atherothrombotic complications in adult patients with a history of myocardial infarction (myocardial infarction was suffered one year or more ago) and a high risk of atherothrombotic complications;
for the prevention of atherothrombotic complications in patients aged 50 years and older with coronary artery disease (CHD) and type 2 diabetes mellitus (T2DM), without a history of myocardial infarction and/or stroke, who underwent percutaneous coronary intervention (PCI).

If you have taken Ticagrelor more than you should have, inform your doctor or contact a medical facility immediately. Take the medicine package with you. You may have an increased risk of bleeding.
Symptoms of overdose
Adverse reactions that may occur with an overdose include shortness of breath and cardiac arrhythmias.
Treatment
In case of an overdose, you will receive symptomatic therapy (a complex of medical procedures to eliminate the symptoms). If bleeding develops, you will receive appropriate supportive measures.

Like all medications, Ticagrelor can cause undesirable reactions, but they do not occur in everyone. Stop taking Ticagrelor and seek immediate medical attention if any of the following serious adverse reactions occur:
• Signs of bleeding, such as:
- severe bleeding or bleeding that cannot be stopped, or prolonged bleeding;
- pink, red, or brown urine (hematuria) (may occur frequently in no more than 1 in 10 people);
– vomiting red blood or vomiting that looks like "coffee grounds", red or black stools (similar to tar) (signs of gastrointestinal bleeding) (it can occur frequently – no more than 1 person out of 10);
- cough with blood or blood clots (hemoptysis) (may occur frequently – no more than 1 person out of 10); - internal bleeding (for example, retroperitoneal bleeding), signs of which may include dizziness and a feeling of nausea (may occur infrequently – no more than 1 person out of 100).
• Signs of a certain type of stroke that is caused by a brain hemorrhage (intracranial hemorrhage), such as:
- sudden numbness or weakness of the arm, leg or face, especially if they appear only on one side of the body; - sudden confusion, speech impairment, or difficulty understanding others; - sudden disturbance of walking or loss of balance or coordination;
- sudden dizziness or sudden severe headache for no apparent reason.
Intracranial hemorrhage may occur infrequently – in no more than 1 person out of 100.
Syncope (may occur frequently – no more than 1 person out of 10):
- temporary loss of consciousness due to a sharp decrease in blood flow to the brain.
• Signs of a blood clotting disorder called thrombotic thrombocytopenic purpura, such as: Fever and purple spots (called purpura) on the skin or in the mouth, with or without yellowing of the skin or eyes (jaundice), unexplained severe fatigue or confusion. Thrombotic thrombocytopenic purpura has been reported in a small number of patients treated with ticagrelor (the frequency is unknown – based on the available data, the frequency of occurrence cannot be determined).
• Signs of a severe allergic reaction, including angioedema (may occur infrequently – no more than 1 in 100 people):
- swelling of the face, lips, oropharynx, or tongue, which may make it difficult to breathe or swallow.

(For more information about all possible adverse reactions, see the leaflet)

Do not take Ticagrelor:
• if you are allergic to ticagrelor or any other components of the drug listed in section 6 of the leaflet;
• if you have bleeding, such as bleeding from ulcers of the stomach or intestines (active pathological bleeding); • if you had a cerebral hemorrhage (intracranial hemorrhage);
• if you have severe liver disease (severe liver failure);
• if you are taking powerful CYP3A4 inhibitors at the same time, for example, any of the following medications:
- ketoconazole (for the treatment of fungal infection);
- clarithromycin (for the treatment of bacterial infection);
- nefazodone (an antidepressant);
- ritonavir and atazanavir (for the treatment of HIV infection and AIDS);
• if your age is less than 18 years old;
• If you are pregnant or breastfeeding.

If you think that any of the above applies to you, tell your doctor about it.

Tell your doctor that you are taking, have recently taken, or may start taking any other medications.
Your doctor needs to know about the medications you are taking in order to take into account possible adverse reactions that may develop due to the interaction of various medications with Ticagrelor, and possibly adjust the doses of medications you are taking, for example:
• rifampicin (used to treat bacterial infections, including tuberculosis); • phenytoin (used to treat seizures);
• Carbamazepine (used to treat seizures);
• phenobarbital (used to treat seizures and as a sedative); • Digoxin (used to treat cardiac arrhythmias and heart failure);
• cyclosporine (used to reduce the overreaction of the immune system);
• statins (namely: simvastatin, lovastatin, atorvastatin, rosuvastatin – used to reduce cholesterol in the blood); • blockers of "slow" calcium channels (for example, diltiazem, verapamil – used to treat cardiac arrhythmias, high blood pressure and coronary heart disease);
(for a more detailed list of medications, see the instructions in the leaflet)

Registration certificate holder
JSC Biochemist, Russian Federation
15A Vasenko St., Saransk, Republic of Mordovia, 430030
Manufacturer
JSC Biochemist, Russian Federation
Address: 15A Vasenko str., Saransk, 430030, Republic of Mordovia
Phone number: +7 (8342) 38 03 68
Email: biohimic@promomed.pro
Internet address: promomed.ru
Organization that accepts consumer claims
JSC Biochemist, Russian Federation
Address: 15A Vasenko str., Saransk, 430030, Republic of Mordovia
Phone number: 8 800 222 95 63; 8 800 777 86 04 ( around the clock)
Email: hot_line@promomed.pro

Keep the medicine out of the reach of children. Do not take the drug after the expiration date (shelf life) indicated on the carton after "Good before". The expiration date is the last day of the given month. Store at temperatures below 30 ° C. Store in the original packaging (pack).

The drug belongs to the prescription category.